Response to Antimalarial Agents in Cutaneous Lupus Erythematosus

Chang, Aileen Y.; Piette, Evan W.; Foering, Kristen; TenHave, Thomas R.; Okawa, Joyce; Werth, Victoria P.

doi:10.1001/archdermatol.2011.191

Cited by 120 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to this, one can search for Anti-La [6] [8] [11], which shows positivity when above 10.0 U/mL, and the patient has a value lower than 7.0 U/mL, which can also be present in the disease and comes according to the literature, because Anti-La is found in only approximately 10% of lupus carriers [6] Treatment can be done by topical sunscreens, steroids and calcineurin inhibitors, while more severe conditions can be treated with hydroxychloroquine and systemic steroids [28] [29] [30] [31]. The patient was duly approached, being treated with hydroxychloroquine 400 mg/day and together with the use of sunscreen.…”

Section: Discussionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Martins¹,

Miguel²,

Anjos³

et al. 2017

JBM

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly women, presents several clinical manifestations and has no known exact cause. The skin is one of the organs that can be affected, with subacute cutaneous lupus erythematosus (SCLE) being one of the classifications according to cutaneous lupus erythematosus lesions. SCLE is commonly found in young to middle age women and carries characteristics related to sun exposure. In this report, there is a rare case of a male and elderly patient that presents SCLE subgroup initially asymptomatic, with subsequent appearance of macular skin lesions and vitiligo appearance. This is an important case to alert health professionals that the disease can manifest itself and open its clinical profile even in patients of sex and unusual ages.

show abstract

Section: Discussionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Martins¹,

Miguel²,

Anjos³

et al. 2017

JBM

View full text Add to dashboard Cite

show abstract

“…Lupus profundus, however, did not improve. In 2011, Chang et al (19) reported improvement in 67% of their patients treated with a combination of HCQ/ MPC (n = 15) and in 33% of their cases treated with a combination of CQ/MPC (n = 6).…”

Section: Discussionmentioning

confidence: 99%

Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?

Benoit¹,

Goebeler²

2015

Acta Derm Venerol

View full text Add to dashboard Cite

Treatment of recalcitrant cutaneous lupus erythematosus (CLE) is challenging. In situations where conventional treatment approaches fail mepacrine - an antimalarial/antiinflammatory drug that has fallen into oblivion in the last decades - might still be a promising option. We retrospectively analysed medical records of 10 patients with refractory CLE that were treated with mepacrine (100-200 mg/day) as mono- or combination therapy for various time intervals between 2001 and 2013 at the University Hospital Würzburg. Mepacrine was generally well tolerated. Side effects were mild and usually resolved after reduction or cessation. Over 50% of the patients experienced amelioration of their symptoms despite a previously recalcitrant clinical course. Altogether, our data demonstrate that mepacrine still remains a useful and effective therapeutic option for other-wise treatment-resistant CLE.

show abstract

“…Quinacrine was started in the majority (86.1%, n=241) of the remaining 280 due to hydroxychloroquine refractoriness, consistent with studies on its efficacy for recalcitrant disease. 3 Following initiation, quinacrine was discontinued in 50.4% (n=141), hydroxychloroquine in 44.5% (n=237), and chloroquine in 62.2% (n=61). Patients on these medications are not mutually exclusive as most were on either hydroxychloroquine or chloroquine in combination with quinacrine.…”

Section: To the Editormentioning

confidence: 99%